H
Hugo M. Horlings
Researcher at Netherlands Cancer Institute
Publications - 129
Citations - 18740
Hugo M. Horlings is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 46, co-authored 106 publications receiving 15805 citations. Previous affiliations of Hugo M. Horlings include BC Cancer Agency & University of Amsterdam.
Papers
More filters
Journal ArticleDOI
The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.
Irida Kastrati,Stacey E. P. Joosten,Svetlana E. Semina,Luis H. Alejo,Svitlana D. Brovkovych,Joshua D. Stender,Hugo M. Horlings,Marleen Kok,Elaine T. Alarid,Geoffrey L. Greene,Sabine C. Linn,Wilbert Zwart,Jonna Frasor +12 more
TL;DR: Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.
Journal ArticleDOI
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.
Kai-Keen Shiu,D Wetterskog,Alan Mackay,Rachael Natrajan,Maryou B. Lambros,David Sims,I. Bajrami,Rachel Brough,Jessica Frankum,Rachel Sharpe,Caterina Marchiò,Hugo M. Horlings,Fabien Reyal,M van der Vijver,Nicholas C. Turner,Jorge S. Reis-Filho,Christopher J. Lord,Alan Ashworth +17 more
TL;DR: It is shown that only a fraction of the ERBB2-amplified breast tumour lines are truly addicted to the ER BB2 oncogene at the mRNA level and display a heterogeneous set of additional genetic dependencies, suggesting that TFAP2C represents a genetic dependency in some ERBB 2+ve breast cancer cells.
Journal ArticleDOI
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
Iris Nederlof,Iris Nederlof,Davide De Bortoli,Yacine Bareche,Bastien Nguyen,Michiel de Maaker,Gerrit K. J. Hooijer,Laurence Buisseret,Marleen Kok,Marcel Smid,Gert Van den Eynden,Arie B. Brinkman,Jan Hudecek,Jan Koster,Christos Sotiriou,Denis Larsimont,John W.M. Martens,Marc J. van de Vijver,Hugo M. Horlings,Roberto Salgado,Elia Biganzoli,Christine Desmedt +21 more
TL;DR: There is a lower inter-pathologist concordance for cell-specific quantification as compared to overall infiltration quantification and the need for standardized immune characterization beyond TIL is emphasized.
Journal ArticleDOI
Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry
Lillian M. Smyth,Qin Zhou,Bastien Nguyen,Celeste Yu,Eva M Lepisto,Monica Arnedos,Michael J Hasset,Michele LeNoue-Newton,Natalie M. Blauvelt,Semih Dogan,Christine M. Micheel,Chetna Wathoo,Hugo M. Horlings,Jan Hudecek,Benjamin Gross,Ritika Kundra,Shawn M. Sweeney,Jianjiong Gao,Nikolaus Schultz,Andrew Zarski,Stuart Gardos,Jocelyn A. Lee,Seth Sheffler-Collins,Ben Ho Park,Charles L. Sawyers,Fabrice Andre,Mia A. Levy,Funda Meric-Bernstam,Philippe L. Bedard,Alexia Iasonos,Deborah Schrag,David M. Hyman,David M. Hyman +32 more
TL;DR: The feasibility of using a novel and publicly accessible clincogenomic registry to define outcomes in a rare genomically defined cancer subtype is demonstrated, an approach with broad applicability to precision oncology.
Journal ArticleDOI
Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer
Bastien Nguyen,Bastien Nguyen,David Venet,Matteo Lambertini,Matteo Lambertini,Christine Desmedt,Roberto Salgado,Hugo M. Horlings,Françoise Rothé,Christos Sotiriou +9 more
TL;DR: It is hypothesized that TP53-mutant premalignant lesions could be less susceptible to the protective effect of an early parity, which might explain the difference of parity-induced protection according to breast cancer subtypes.